Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 2538 • 2014 ACR/ARHP Annual Meeting
Ultrasound-Guided Core Needle Biopsy of the Major Salivary Glands Is a Safe and Useful Diagnostic Tool in the Evaluation of Suspected or Established Sjögren’s Syndrome
Anand Narayan¹, Thomas Grader-Beck², Julius Birnbaum³, Jean Kim⁴, Qing Kay Li⁵, Deborah Belchis⁵, Joel Fradin¹ and Alan N. Baer⁶, ¹Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Ultrasound-guided core needle biopsy (CNB) has greater inherent risks than fine-needle aspiration for the diagnosis of major salivary gland neoplasms, but provides tissue for…
Abstract Number: 1798 • 2014 ACR/ARHP Annual Meeting
Interaction Between Innate Immunity and Anti-Ro52 Antibodies is Critical for the Induction of Sjogren’s Syndrome-like Disease in Mice
Paulina Kaplonek¹, Barbara Szczerba², Nina Wolska¹, Paulina Rybakowska¹, Arkadiusz Klopocki¹, Paromita Dey³, Astrid Rasmussen⁴, Kimberly Hefner⁵, Stephen Young⁶, Donald U. Stone⁷, David M. Lewis⁶, Lida Radfar⁸, R. Hal Scofield⁴, Kathy Moser Sivils⁹, Harini Bagavant⁹ and Umesh Deshmukh⁹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Virginia, Charlottesville, VA, ³Department of Medicine, University of Virginia, Charlottesville, VA, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose . Autoantibodies reactive with Ro52 are present in almost 70% of Sjögren’s syndrome (SS) patients. This study was undertaken to investigate the role of…
Abstract Number: 149 • 2014 ACR/ARHP Annual Meeting
Automated Digital Analysis of Major Salivary Gland Ultrasound Images
Daniel S. Hammenfors¹, Preben G. Nes², Johan G. Brun¹, Roland Jonsson¹ and Malin V. Jonsson³, ¹Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ²Sogn and Fjordane University College, Førde, Norway, ³Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway
Background/Purpose Primary Sjögren’s syndrome (pSS) is an autoimmune chronic inflammatory disease mainly affecting the salivary and lacrimal glands, with symptoms such as dryness of the…
Abstract Number: 2537 • 2014 ACR/ARHP Annual Meeting
Diagnostic Accuracies of Sialography and Salivary Ultrasonography in Sjogren’s Syndrome Patients: A Meta-Analysis
Young Ho Lee¹ and Gwan Gyu Song², ¹Internal Medicine, Rheumatology, Korea University Medical Center, Seoul, South Korea, ²Div of Rheum, Dept of Int Medicine, Guro Hospital, Korea Univ College of Medicine, Seoul, South Korea
Background/Purpose Ultrasonography (US) may come to replace conventional invasive examinations in clinical practice. However, the diagnostic accuracy of salivary US has not been clearly compared…
Abstract Number: 1605 • 2014 ACR/ARHP Annual Meeting
Elevated Regulatory Mediators and Interferon Gamma Associated Responses, but Not Interferon Alpha, BLyS or IP-10, Accompany High-Titer Anti-Ro Autoantibodies in Asymptomatic Mothers of Children with Neonatal Lupus
Peter M. Izmirly¹, Robert M. Clancy², Melissa Munroe³, Sara Rasmussen², Amit Saxena^2,4, Jose U. Scher², Aikaterini Thanou⁵, Stan Kamp⁶, Joan T. Merrill⁷, Jill P. Buyon² and Judith James⁸, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Rheumatology, New York University School of Medicine, New York, NY, ⁵Arthritis and Clinical Immunology Reseach Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Mothers of children with neonatal lupus offer a unique opportunity to study the drivers and consequences of autoantibody production in the absence of ongoing…
Abstract Number: L3 • 2014 ACR/ARHP Annual Meeting
Low Protein A20 Expression in Minor Salivary Glands Is Associated with Lymphoma Development in Primary Sjögren’s Syndrome
Svein Joar A. Johnsen¹, Einar Gudlaugsson², Ivar Skaland², Emiel Janssen², Malin V. Jonsson³, Lars Helgeland⁴, Ellen Berget⁵, Roland Jonsson⁶ and Roald Omdal¹, ¹Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ²Stavanger University Hospital, Stavanger, Norway, ³Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, ⁴Haukeland University Hospital, Bergen, Norway, ⁵University of Bergen, Bergen, Norway, ⁶Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: Patients with primary Sjogrens syndrome (pSS) have an increased risk of developing lymphomas, especially of the subtype mucosa-associated lymphoid tissue (MALT) lymphoma. Chronic antigen…
Abstract Number: 2536 • 2014 ACR/ARHP Annual Meeting
The Sjögren’s Syndrome Responder Index, a Data-Driven Combined Endpoint, Could Detect Biologics Efficacy
Divi Cornec¹, Valerie Devauchelle-Pensec², Xavier Mariette³, Sandrine Jousse-Joulin⁴, Jean-Marie Berthelot⁵, Aleth Perdriger⁶, Xavier Puéchal⁷, Véronique le Guern⁸, Jean Sibilia⁹, Jacques Gottenberg¹⁰, Laurent Chiche¹¹, Eric Hachulla¹², Pierre-Yves Hatron¹³, Vincent Goëb¹⁴, Gilles Hayem¹⁵, Jacques Morel¹⁶, Charles Zarnitsky¹⁷, Jean Jacques Dubost¹⁸, Raphaèle Seror¹⁹, Jacques-Olivier Pers²⁰, Emmanuel Nowak²¹ and Alain Saraux²², ¹Department of rheumatology and unit of immunology, Brest Occidentale University, Brest, France, ²Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France, ³rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France, ⁴Rheumatology, CHU Brest, Brest, France, ⁵Rheumatology, CHU Nantes (Nantes University Hospital), Nantes, France, ⁶Rhumatologie, Rennes, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁸Department of Internal Medicine, Hôpital Cochin, Paris, France, ⁹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁰Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹147 Boulevard Baille, CHU Marseille, Marseille, France, ¹²Internal Medicine, National Scleroderma Centre, Lille CEDEX, France, ¹³CHU Lille, Lille, France, ¹⁴Rheumatology, Amiens University Hospital, Amiens, France, ¹⁵CHU Bichat, Paris, France, ¹⁶Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, ¹⁷Rheumatology, Le Havre General Hospital, Le Havre, France, ¹⁸Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ¹⁹Rheumatology, Université Paris Sud, Le Kremlin Bicêtre, France, ²⁰CHU Brest, Brest, France, ²¹CIC, CHU Brest, Brest, France, ²²Rheumatology, CHU de la Cavale Blanche and Université Bretagne occidentale, Brest Cedex, France
Background/Purpose Efficacy of rituximab remains debated in primary Sjögren’s syndrome (pSS), but that could be partly due to the absence of validated endpoint. To determine…
Abstract Number: 1329 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical and Serological Features of Childhood Sjögren Syndrome Based on the Presence or Absence of Parotitis
Jay Mehta¹, Namrata Singh² and Scott Lieberman³, ¹Pediatrics, Children's Hospital at Montefiore/Albert Einstein College of Medicine, Bronx, NY, ²Medicine, University of Iowa, Iowa City, IA, ³Pediatrics (Division of Rheumatology), University of Iowa Children's Hospital, Iowa City, IA
Background/Purpose: Sjögren syndrome is a complex autoimmune disease that affects lacrimal and salivary glands with the potential to cause damage to other organs. Diagnosis of…
Abstract Number: 2534 • 2014 ACR/ARHP Annual Meeting
Ocular Surface Temperature in Early Sjogren’s Syndrome and Established Disease
Andreea Coca¹, Ranjini Kottaiyan², Mircea Coca³, Debbie Campbell⁴, Holly Hindman² and James Aquavella², ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Ophtalmology, University of Rochester, Rochester, NY, ³Ophtalmology, University of Texas Medical Branch, Galveston, TX, ⁴Allergy, Immunology and Rheumatology, Univerity of Rochester, Rochester, NY
Background/Purpose Due to a variety of factors it is challenging to make a definite diagnosis in the early stages of Sjögren’s syndrome (SS). The ocular…
Abstract Number: 1236 • 2014 ACR/ARHP Annual Meeting
IgG4 Immunostaining Is Common but Not Specific in Orbitbal Inflammatory Diseases
James T. Rosenbaum^1,2, Amanda Wong³, Patrick Stauffer³, Megan Troxell⁴, Donald Houghton⁵, Dongseok Choi⁶, Christine Harrington⁷, David Wilson⁸, Hans Grossniklaus⁹, Roger Dailey³, John Ng³, Eric Steele³, Patrick Yeatts¹⁰, Peter Dolman¹¹, Valerie White¹¹, Craig Czyz¹², Jill Foster¹², Deepak Edward¹³, Hind Alkatan¹³, Don Kikkawa¹⁴, Bobby Korn¹⁵, Dinesh Selva¹⁶, Gerald Harris¹⁷, Michael Kazim¹⁸, Payal Patel¹⁸ and Stephen R. Planck¹⁹, ¹OHSU, Portland, OR, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³Oregon Health & Science University, Portland, OR, ⁴Pathology, Oregon Health and Science University, Portland, OR, ⁵Pathology, Oregon Health & Science University, Portland, OR, ⁶Casey Eye Institute, Oregon Health and Science University, Portland, OR, ⁷Integrated Genomics, Oregon Health & Science University, Portland, OR, ⁸Casey Eye Institute/Ophthalmology, Oregon Health & Science University, Portland, OR, ⁹Ophthalmology, Emory University, Atlanta, GA, ¹⁰Ophthalmology, Wake Forest University, Winston-Salem, NC, ¹¹University of British Columbia, Vancouver, BC, Canada, ¹²Ohio State Univeristy, Columbus, OH, ¹³King Khaled Eye Hospital, Riyadh, Saudi Arabia, ¹⁴Ophthalmology, University of California, San Diego, San Diego, CA, ¹⁵University of California, San Diego, San Diego, CA, ¹⁶Royal Adelaide Hospital, Adelaide, Australia, ¹⁷Medical College of Wisconsin, Milwaukee, WI, ¹⁸Columbia University, New York City, NY, ¹⁹Casey Eye Inst/Ophthalmology, Oregon Health & Science University, Portland, OR
Background/Purpose: IgG4-related disease is an emerging clinical entity which frequently involves tissue within the orbit. In order to appreciate the implications of IgG4 immunostaining, we…
Abstract Number: 2552 • 2014 ACR/ARHP Annual Meeting
Effectiveness and Safety of Low-Dose Cyclosporine a in Patients with Primary Sjögren’s Syndrome (pSS) with Articular Involvement – Results of a Pilot Study
Claudia Kedor¹, Jan Zernicke¹, Anja Hagemann², Kathrin Mattat¹, Gerd Burmester¹ and Eugen Feist¹, ¹Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ²Department of Rheumatology and Immunology, Charité University Medicine, Berlin, Germany
Background/Purpose Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease, where musculoskeletal manifestations are usually treated by symptomatic measures and different conventional DMARDs by off-label…
Abstract Number: 1169 • 2014 ACR/ARHP Annual Meeting
Hippocampal Atrophy Is Associated with Anti-NR2 Antibodies in Patients with Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome
Maria B Lauvsnes¹, Mona K Beyer², Jan T Kvaløy^3,4, Ole J Greve⁵, Simone Appenzeller⁶, Erna Harboe⁷, Anne B Tjensvoll⁸, Lasse G Gøransson⁷ and Roald Omdal⁹, ¹Department of Internal Medicine, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway, ²Department of Radiology and Nuclear medicine, Oslo University Hospital, National Hospital, Oslo, Norway, ³Research Department, Stavanger University Hospital, Stavanger, Norway, ⁴Department of Mathematics and Natural Sciences, University of Stavanger, Stavanger, Norway, ⁵Department of Radiology, Stavanger University Hospital, Stavanger, Norway, ⁶Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil, ⁷Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁸Department of Neurology, Stavanger University Hospital, Stavanger, Norway, ⁹Department of Internal Medicin, Clinical Immunology Unit, Stavanger University Hospital, Stavanger, Norway
Background/Purpose: Antibodies against the NR2 subtype of the NMDA-receptor (anti-NR2 antibodies) are detected in patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (SS).…
Abstract Number: 2551 • 2014 ACR/ARHP Annual Meeting
Presence of Germinal Centers at Baseline Is Associated with Clinical Response of Glandular Essdai Domain after Abatacept Treatment in Primary Sjogren’s Syndrome
Erlin A. Haacke¹, Frans G.M. Kroese², Petra M. Meiners³, Bert van der Vegt¹, Arjan Vissink⁴, Fred K.L. Spijkervet³ and Hendrika Bootsma², ¹Pathology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ³Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: Abatacept inhibits the costimulatory interaction of T-lymphocytes and antigen-presenting cells. Treatment of early and active primary Sjögren's Syndrome (pSS) with abatacept decreases disease activity.…
Abstract Number: 985 • 2014 ACR/ARHP Annual Meeting
Labial Salivary Gland Antibody-Secreting Cell Specificity and Characteristics in Sjögren’s Patients
Kristi A. Koelsch¹, Jacen Maier-Moore², Kenneth Smith³, Christopher Lessard³, Astrid Rasmussen⁴, Biji Kurien³, Umesh Deshmukh³, A. Darise Farris³, Judith A. James⁵, Kathy L. Sivils⁴, R. Hal Scofield⁶ and Mark Coggeshall⁷, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, ²Dept. of Clinical Laboratory Science, University of Texas at El Paso, El Paso, TX, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁷Immunobiology and Cancer Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose Studies were approved by the OMRF and the University of Oklahoma Health Sciences Center Institutional Review Boards. Samples and data were obtained from 9…
Abstract Number: 2977 • 2014 ACR/ARHP Annual Meeting
Distinct Serum Protein Signature and Novel Biomarkers of primary Sjogren’s Syndrome Revealed by comprehensive High-Throughput Proteomic Analysis
Ayumi Nishikawa¹, Katsuya Suzuki², Yoshiaki Kassai³, Yuumi Gotou⁴, Takahiro Miyazaki³, Maiko Takiguchi⁵, Masaru Takeshita¹, Atsuko Murota², Rimpei Morita⁶, Akihiko Yoshimura⁶ and Tsutomu Takeuchi², ¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ⁴Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Tokyo, Japan, ⁵Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Japan, ⁶Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: The EULAR SS Disease Activity Index (ESSDAI) is currently used as an objective evaluation method of clinical disease activity in clinical research into primary…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].